Skip to main content
MCHX
NASDAQ Technology

Marchex Seeks Shareholder Approval for $16.5M Related-Party Acquisition of Archenia

Analysis by Wiseek AI
Sentiment info
Neutral
Importance info
8
Price
$1.52
Mkt Cap
$67.368M
52W Low
$1.322
52W High
$2.31
Market data snapshot near publication time

Summary

Marchex filed a definitive proxy statement seeking shareholder approval for its $16.5 million acquisition of Archenia, a related-party transaction involving convertible notes and earn-out shares that could result in significant dilution.


Key Events

  • Acquisition Details

    Marchex plans to acquire Archenia for $10 million in 6% convertible promissory notes (convertible at $1.80/share) and up to 4 million Class B common shares as earn-out consideration.

  • Related-Party Transaction

    Marchex's Chairman and Vice Chairman are among the sellers of Archenia, making this a related-party transaction requiring a 'Majority of the Minority Vote' for approval.

  • Shareholder Vote Scheduled

    A special meeting of stockholders is scheduled for July 1, 2026, to vote on the acquisition and related proposals.

  • Potential Dilution

    The transaction could result in the issuance of up to 9,555,556 new shares, representing approximately 21.4% potential dilution to existing shareholders.


Analysis

Marchex has filed a definitive proxy statement for a special meeting on July 1, 2026, to approve the acquisition of Archenia, a related-party transaction valued at $16.5 million. The consideration includes $10 million in convertible promissory notes and up to 4 million earn-out shares. This transaction is significant, representing approximately 24.5% of Marchex's current market capitalization and potentially diluting existing shareholders by up to 21.4% if all convertible notes and earn-out shares are issued. The related-party nature, with Marchex's Chairman and Vice Chairman as sellers, necessitates a 'Majority of the Minority Vote' for approval, a key governance safeguard. Notably, the convertible notes are priced at $1.80 per share, which is a premium to Marchex's current stock price of $1.52. While strategically aimed at enhancing AI capabilities, the acquisition introduces risks, including Archenia's historical net losses and a disclosed material weakness in internal controls.

At the time of this filing, MCHX was trading at $1.52 on NASDAQ in the Technology sector, with a market capitalization of approximately $67.4M. The 52-week trading range was $1.32 to $2.31. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MCHX - Latest Insights

MCHX
Jun 05, 2026, 4:15 PM EDT
Filing Type: DEFM14A
Importance Score:
8
MCHX
May 26, 2026, 4:35 PM EDT
Filing Type: PREM14A
Importance Score:
8
MCHX
May 14, 2026, 4:15 PM EDT
Filing Type: 10-Q
Importance Score:
7
MCHX
May 13, 2026, 4:26 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
MCHX
May 13, 2026, 4:20 PM EDT
Filing Type: 8-K
Importance Score:
8
MCHX
May 12, 2026, 4:23 PM EDT
Source: Wiseek News
Importance Score:
8
MCHX
May 12, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
8
MCHX
Apr 17, 2026, 4:15 PM EDT
Filing Type: 10-K/A
Importance Score:
7
MCHX
Apr 15, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
8
MCHX
Mar 26, 2026, 8:45 AM EDT
Filing Type: 10-K
Importance Score:
8